An artificial membrane binding protein-polymer surfactant nanocomplex facilitates stem cell adhesion to the cartilage extracellular matrix by Cuahtecontzi Delint, Rosalia et al.
                          Cuahtecontzi Delint, R., Day, G. J., Macalester, W. J. P., Kafienah,
W., Xiao, W., & Perriman, A. W. (2021). An artificial membrane
binding protein-polymer surfactant nanocomplex facilitates stem cell
adhesion to the cartilage extracellular matrix. Biomaterials, 276,
120996. [120996]. https://doi.org/10.1016/j.biomaterials.2021.120996
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1016/j.biomaterials.2021.120996
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://doi.org/10.1016/j.biomaterials.2021.120996 .Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Biomaterials 276 (2021) 120996
Available online 28 June 2021
0142-9612/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
An artificial membrane binding protein-polymer surfactant nanocomplex 
facilitates stem cell adhesion to the cartilage extracellular matrix 
Rosalia Cuahtecontzi Delint a,b, Graham J. Day a, William J.P. Macalester a,b, Wael Kafienah a, 
Wenjin Xiao a,**, Adam W. Perriman a,c,* 
a School of Cellular and Molecular Medicine, University of Bristol, BS8 1TD, UK 
b Bristol Centre for Functional Nanomaterials, University of Bristol, BS8 1FD, UK 
c BrisSynBio Synthetic Biology Research Centre, University of Bristol, BS8 1TQ, UK   
A R T I C L E  I N F O   
Keywords: 
Articular cartilage repair 
Stem cell therapy 
Cell membrane re-engineering 
Protein-polymer surfactant complex 
Cell adhesion 
A B S T R A C T   
One of the major challenges within the emerging field of injectable stem cell therapies for articular cartilage (AC) 
repair is the retention of sufficient viable cell numbers at the site of injury. Even when delivered via intra- 
articular injection, the number of stem cells retained at the target is often low and declines rapidly over time. 
To address this challenge, an artificial plasma membrane binding nanocomplex was rationally designed to 
provide human mesenchymal stem cells (hMSCs) with increased adhesion to articular cartilage tissue. The 
nanocomplex comprises the extracellular matrix (ECM) binding peptide of a placenta growth factor-2 (PlGF-2) 
fused to a supercharged green fluorescent protein (scGFP), which was electrostatically conjugated to anionic 
polymer surfactant chains to yield [S− ]scGFP_PlGF2. The [S− ]scGFP_PlGF2 nanocomplex spontaneously inserts 
into the plasma membrane of hMSCs, is not cytotoxic, and does not inhibit differentiation. The nanocomplex- 
modified hMSCs showed a significant increase in affinity for immobilised collagen II, a key ECM protein of 
cartilage, in both static and dynamic cell adhesion assays. Moreover, the cells adhered strongly to bovine ex vivo 
articular cartilage explants resulting in high cell numbers. These findings suggest that the re-engineering of hMSC 
membranes with [S− ]scGFP_PlGF2 could improve the efficacy of injectable stem cell-based therapies for the 
treatment of damaged articular cartilage.   
1. Introduction 
Articular cartilage (AC) damage arising from trauma or osteoarthritis 
is extremely common, and is a major cause of pain and disability in 
aging populations [1]. Due to the limited self-renewal capacity of 
cartilage, surgical intervention has remained the leading treatment to 
help alleviate pain and improve joint mobility. Unfortunately, surgical 
approaches, such as bone marrow stimulation and osteochondral auto-
graft transplantation, are limited by tissue availability, immunological 
responses, and the high demands of invasive surgeries, resulting in only 
short-term effectiveness on small defects [2]. Accordingly, there is an 
unmet clinical need for new treatment strategies for AC damage. 
Injectable stem cell therapies are in pre-clinical development for a 
range of indications [2–4] and are emerging as next generation candi-
dates for AC damage [5]. Intra-articular (IA) injection of stem cells is 
clinically facile and relatively non-invasive, making it a potentially 
efficient treatment for cartilage repair. Several clinical trials have now 
concluded that the implantation of stem cells successfully improves knee 
joint mobility and results in the formation of new hyaline-like cartilage 
[6–8]. 
Mesenchymal stem cells (MSCs) have a number of desirable attri-
butes that are key for the development of autologous cell therapies for 
AC repair. They are readily available and can be expanded rapidly, 
exhibit immunomodulatory [9,10] and anti-inflammatory properties 
[11] through secretion of trophic factors that regulate paracrine sig-
nalling [12,13] or extracellular vesicles containing active signalling 
molecules [14,15], and can differentiate into chondrocytes [16]. 
Significantly, a recent study using an immunocompetent transgenic ro-
dent model showed that IA injections of murine MSCs engrafted to 
regenerate cartilage in full-thickness defects via a 
nonprogenitor-mediated mechanism [17]. 
The exact mechanisms underlying how MSCs contribute to cartilage 
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repair have not yet been clearly elucidated. Chondrogenic differentia-
tion, immunomodulation, and the production of paracrine signalling 
mostly likely play a key role [18]. Notably, MSCs have been shown to 
engraft and produce new tissue when cells remained in the damaged 
area of cartilage [19,20]. Accordingly, it is becoming apparent that 
transplanted MSCs need to remain at the site of injury in order to achieve 
a significant therapeutic effect. Indeed, a lack of targeting presents a 
potential barrier to the widespread clinical translation of injectable 
MCS-based therapies for AC repair, where off-target effects result in low 
engraftment, even in low flow environments such as the joint capsule 
[21]. For example, in a rabbit model, MSCs that were intra-articularly 
injected into the injured knee were found to migrate to the supra-
patellar bursa (upper knee), to the popliteal fossa (back of the knee 
joint), and to the subchondral femur bone, resulting in low efficacy for 
cartilage repair [22]. 
Such low levels of cell retention in the AC can be rationalised by poor 
cell adhesion at the site of injury post injection, which is mediated by AC 
surface bound anti-adhesive molecules such as lubricin [23]. Ideally, 
after articular implantation, MSCs would migrate to the damaged site by 
following chemoattractant signals released by the disruption of the 
extracellular matrix (ECM). After initial contact, MSCs would roll and 
arrest via adhesion molecule-receptor interactions, followed by cyto-
skeletal rearrangement and engraftment to the ECM [24,25]. Failure to 
accomplish cell–ECM interactions can result in anoikis (cell homeless-
ness) and apoptosis [21]. Therefore, building appropriate interactions 
between MSCs and the ECM is crucial to promote cell viability, reten-
tion, engraftment, and repair. 
Several tissue engineering approaches been developed in order to 
improve stem cell retention, mainly by utilizing soft scaffolding mate-
rials. For instance, cells have been implanted using soft biocompatible 
matrices such as collagen [26] or alginate [27] hydrogels [28]. Although 
these substrates provide additional support for cell survival, retention 
and wound healing, major hurdles still remain, such as cartilage 
biomechanical compatibility and foreign body reactions [29]. Indeed, 
despite biodegradability and extrudability being attractive properties of 
hydrogel-based scaffolds, they are susceptible to mechanical failure, as 
most hydrogels undergo bulk erosion [30]. Moreover, when hydrogels 
are used for AC regeneration, there is a trade-off between stiffness to 
support the mechanical loads and degradability due to compression 
[31]. 
Cell membrane re-engineering is emerging as a new approach to 
improve the targeting performance of therapeutic stem cells in regen-
erative medicine. For instance, Cheng et al. re-engineered the membrane 
of MSCs using surface chemistry to covalently conjugate E-selectin 
binding peptides in order to modulate cell rolling and adhesion [32]. 
Another notable example was by Lo et al., who used non-covalent in-
teractions to decorate MSCs with the human antibody (IgG1) fused to 
P-selectin glycoprotein ligand-1 [33]. These modified cells showed su-
perior rolling and adhesion capacities for P-selectin- and E-selectin--
modified surfaces, leading to enhanced MSC tethering to human 
umbilical vein endothelial cells (HUVECs). Similarly, a recent study by 
Wu et al. demonstrated that MSCs were directed to and retained at 
infarcted heart tissue after membrane biotinylation and conjugation to a 
streptavidin-intermediated antibody specific to intercellular cell adhe-
sion molecules [34]. Nevertheless, to our knowledge, a MSC membrane 
re-engineering strategy for improved articular cartilage adhesion has 
not been reported. 
Previously, our group described a new cell membrane re-engineering 
methodology, where exogenous protein molecules could be directly 
displayed on the plasma membrane of stem cells to provide additional 
functionality. This was achieved by utilizing genetically or chemically 
supercharged proteins that are electrostatically conjugated to anionic 
polymer surfactant molecules with high membrane binding affinities. 
We have demonstrated that several functional proteins can be readily 
displayed on the surface of human MSCs (hMSCs) to improve their 
performance both in vitro and in vivo. These include, the oxygen-binding 
protein myoglobin, which improved the quality and distribution of in 
vitro engineered cartilage tissue [35], an artificial membrane binding 
thrombin, which facilitated hMSC membrane nucleated fibrin-hydrogel 
scaffold formation [36], and a bacterial adhesion protein chimera that 
directed stem cells to the myocardium [37]. In all cases, conjugation of 
the supercationic protein with the polymer-surfactant increased the 
persistence time of the nanocomplexes at the plasma membrane of the 
hMSCs. 
Here, the conceptual advance is centred on improving cell adhesion 
to AC by displaying an ECM-binding peptide motif from placenta growth 
factor 2 (PlGF2123–14; PlGF2 to simplify) [38] on the membrane of 
hMSCs. To do this, the PlGF2 peptide sequence was incorporated into an 
artificial membrane-binding construct by fusion with a supercharged 
green fluorescent protein (scGFP+36; scGFP for simplicity) [39], which 
was electrostatically conjugated to oxidised polyoxyethylene non-
ylphenyl ether (S− ) to yield [S− ]scGFP_PIGF2 (Fig. 1). A broad range of 
biophysical techniques were used to study the structure of the novel 
fusion protein and resulting nanocomplex, which showed that the pro-
tein structure and functions were preserved and that the PIGF2 peptide 
motif was accessible not obstructed by the scGFP domain. When intro-
duced to hMSCs, the [S− ]scGFP_PIGF2 spontaneously inserted into the 
plasma membrane without cytotoxicity and showed no suppression of 
cell proliferation or differentiation. Notably, hMSCs showed signifi-
cantly increased adhesion to collagen II after modification, under both 
static and dynamic conditions. Moreover, hMSCs modified with [S− ] 
scGFP_PIGF2 showed improved cell adhesion performance on the 
articular surface of live bovine cartilage explants. 
2. Results and discussion 
2.1. Expression and characterisation of the recombinant fusion protein 
scGFP_PIGF2 
The fusion protein scGFP_PlGF2 (Supplementary Table 1) and the 
control protein scGFP were expressed in E. coli, isolated via immobilised 
metal-ion affinity chromatography, and analysed by SDS–PAGE to assess 
purity. Single bands were observed at approximately 32 kDa and 29 kDa 
for scGFP_PlGF2 and scGFP, respectively, and matrix-assisted laser 
desorption/ionisation mass spectrometry (MALDI-MS) gave respective 
molecular weights of 32.110 kDa and 29.275 kDa (Supplementary 
Figure 1 and 2). The difference in m/z ratios between the proteins cor-
responded well with the predicted molecular weight of the PlGF2 pep-
tide (Supplementary Table 2). Given that scGFP_PlGF2 fusion was 
rationally designed to display the PlGF2 peptide when cell membrane 
bound, protein structure modelling was performed via iterative thread-
ing assembly simulations (I-TASSER) to determine the orientation of the 
peptide with respect to the globular scGFP domain [40] (see Experi-
mental section 4.8). Although no crystal structure is available for scGFP, 
these models predicted that the scGFP domain folded into a β-barrel 
similarly to superfolder GFP (the template protein structure for scGFP) 
with the PIGF2 domain extended out away from the C-terminus of the 
scGFP (Supplementary Fig. 3a and b) [39,41]. Consequently, experi-
mental studies comparing scGFP_PlGF2 to scGFP were undertaken to 
evaluate the folding of the scGFP domain and confirm the steric acces-
sibility of the PlGF2 peptide. 
Deconvolution of near-UV synchrotron radiation–circular dichroism 
(SR–CD) spectra (Fig. 2a and Supplementary Table 3) revealed compa-
rable secondary structure proportions between scGFP and scGFP_PlGF2, 
and UV–vis and fluorescence spectroscopy studies confirmed their near 
identical optical properties (Supplementary Figure 4 and 5), verifying 
the correct folding and fluorophore maturation of the scGFP domain in 
scGFP_PlGF2. Dynamic light scattering (DLS) measurements revealed 
that the addition of the PlGF2 peptide sequence to scGFP increased the 
hydrodynamic diameter from 4.6 ± 0.3 nm to 5.6 ± 0.7 nm (Fig. 2b). 
Synchrotron radiation–small angle X-ray scattering (SR–SAXS) high-
lighted structural differences between scGFP_PlGF2 and scGFP at higher 
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resolution. 
Resolution (Supplementary Figure 6 and Supplementary Table 4). 
The presence of the PlGF2 peptide resulted in a 7 Å increase to the radius 
of gyration (Rg) and a 15 Å increase in the maximum dimension of the 
pair distribution function (Dmax; Fig. 2c and Supplementary Table 4), 
which supported the DLS data. The Porod exponent (PE) for 
scGFP_PlGF2, a measure of molecule flexibility, decreased when 
compared to scGFP, signifying greater structural flexibility (Supple-
mentary Table 4) [42]. Ab initio models were constructed using the 
SR–SAXS data to further investigate the conformation and hence the 
steric accessibility of the PlGF2 peptide (see Experimental section 4.8). 
The resulting scGFP_PlGF2 models exhibited high-aspect ratios with a 
Fig. 1. Schematic representation of the nanocomplex. a Three-dimensional ribbon model of scGFP_PIGF2 (orange) enveloped within a surface model signifying the 
electrostatic potential of the protein (blue: positive; red: negative). b The anionic polymer surfactant that was electrostatically conjugated to the surface of 
scGFP_PIGF2. c Graphical representation of the nanocomplex [S− ]scGFP_PIGF2 (anionic polymer surfactant is blue and the protein is orange) embedded within a cell 
membrane (magenta spheres with white tails) and bound to extracellular matrix (yellow web). (For interpretation of the references to colour in this figure legend, the 
reader is referred to the Web version of this article.) 
Fig. 2. Structural and biophysical characterisation of the nanoconstructs. a Synchrotron radiation–circular dichroism spectra from scGFP (green circles), 
scGFP_PlGF2 (orange circles) and [S− ]scGFP_PlGF2 (blue circles) with corresponding fits (solid lines). Data was fitted with BestSel and normalised root-mean-squared 
deviation values for scGFP, scGFP_PlGF2 and [S− ]scGFP_PlGF2 are 0.1436, 0.0570, and 0.0852, respectively. Measurements were taken at 36 ◦C at a concentration of 
0.35 mg mL− 1. b Hydrodynamic diameter numbers distribution obtained by dynamic light scattering for scGFP, scGFP_PlGF2, and [S− ]scGFP_PlGF2. Solid lines 
present averages with standard error displayed as coloured areas, n = 3. Measurements were taken in 400 mM NaCl and 20 mM Tris-HCl buffer at pH 7.5. c The radial 
probability distribution function (P(r)) of the scGFP, scGFP_PlGF2, and [S− ]scGFP_PlGF2. d UV–vis spectroscopy of scGFP_PlGF2 and [S− ]scGFP_PlGF2. Measure-
ments were taken in buffer 400 mM sodium chloride, 20 mM Tris-HCl in pH 7.5. e Fluorescence spectroscopy of scGFP_PlGF2 and [S− ]scGFP_PlGF2, displaying 
excitation (dashed lines) and emission (solid lines) data. Measurements were taken in buffer 400 mM NaCl and 20 mM Tris-HCl at pH 7.5. f Ab initio bead model 
calculated from synchrotron radiation–small angle scattering (SR–SAXS) data, displaying the scGFP_PIGF2 (orange surface) within the [S− ]scGFP_PlGF2 (blue 
spheres) model. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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wide tail region corresponding to the PIGF2 peptide extending away 
from the scGFP moiety (Supplementary Figure 3c). Taken together, 
these data indicated that the scGFP domain was correctly folded and that 
the PlGF2 peptide was likely sterically accessible for ECM binding. 
2.2. Formation and structure of the nanocomplex [S− ]scGFP_PlGF2 
In light of the retention of structure and function by scGFP_PlGF2, 
the anionic polymer surfactant, S− (H19C9-Ph– 
(CH2CH2O)39–O–CH–COO− ), was used to generate an electrostatically- 
stabilised polymer surfactant corona on the surface of the super-
charged fusion protein [35,37,43,44] (Fig. 1). UV–vis spectroscopy from 
the [S− ]scGFP_PlGF2 nanohybrid dispersion revealed a protein positive 
charge:surfactant stoichiometric ratio of at 1.4:1 (Fig. 2d), which indi-
cated a small excess of protein-bound surfactant chains. Deconvolution 
of the SR–CD spectra from [S− ]scGFP_PlGF2 showed a high proportion 
of β-sheet secondary structure, with similar levels to that found in scGFP 
and scGFP_PlGF2 (Fig. 2b and Supplementary Table 3) [41]. The pres-
ervation of the protein tertiary structure was supported by fluorescence 
spectroscopy measurements, which illustrated the retention of scGFP 
fluorophore geometry, with a maximum absorbance at 487 nm and 
excitation at 511 nm (Fig. 2e) [39,41]. 
Zeta potentiometry showed a reduction in the zeta potential upon 
electrostatic assembly, decreasing from +21 ± 0.8 mV for scGFP_PlGF2 
to − 0.5 ± 0.5 mV for [S− ]scGFP_PlGF2 (Supplementary Table 5), 
signifying electrostatically-driven assembly. The formation of compact 
monodisperse nanocomplexes was confirmed by DLS measurements, 
which showed an increase of 3 nm in the hydrodynamic diameter after 
S− binding (Fig. 2b). This was further supported by SR–SAXS, which 
revealed a concomitant increase in Dmax (ca. 1 nm; Fig. 2c) and Rg (ca. 9 
Å; Supplementary Table 4) after polymer surfactant addition, and a 
further decrease in the Porod exponent (PE), likely arising from the 
presence of the flexible polymer surfactant chains (Supplementary 
Table 4). The SR–SAXS data were also used for ab initio bead modelling, 
which gave a discrete, globular, [S− ]scGFP_PlGF2 structure that was 
larger than scGFP_PIGF2, and consistent with the fusion protein sur-
rounded by the S− polymer surfactant corona (Fig. 2f and Supplemen-
tary Figure 7). 
2.3. Nanocomplex assembly at the stem cell plasma membrane 
Both the [S− ]scGFP_PlGF2 nanocomplex and the scGFP_PIGF2 pre-
cursor were not cytotoxic to hMSCs below incubation concentrations of 
12 μM (Supplementary Figure 8 and 9). Accordingly, all subsequent cell 
experiments were performed at 4 μM, which did not inhibit hMSC pro-
liferation with either construct (Supplementary Figure 10). Flow 
cytometry studies revealed a labelling efficiency of 100% for hMSCs 
modified with [S− ]scGFP_PlGF2 or scGFP_PlGF2 after one day (Sup-
plementary Figure 11 and 12), which decayed over a ten-day period 
(Supplementary Figure 13). Live cell confocal fluorescence microscopy 
imaging confirmed that both [S− ]scGFP_PlGF2 and scGFP_PlGF2 
strongly associated with the hMSC plasma membrane after incubation 
(Fig. 3), where the supercationic scGFP_PlGF2 likely interacted via 
electrostatic interactions with anionic sulfated proteoglycans [45], 
while [S− ]scGFP_PlGF2 through membrane bilayer intercalation by the 
nonylphenol tails of the protein-bound polymer surfactant corona 
(Fig. 1) [35,44]. Time-lapse widefield fluorescence microscopy showed 
rapid uptake of the scGFP_PlGF2 by the hMSCs, which was less evident 
with the [S− ]scGFP_PlGF2 nanocomplex (Supplementary Figure 14). 
This is due to the hydrophobic nature of the nanocomplex-cell mem-
brane interaction rather than the coulombic interaction that occurs be-
tween the scGFP moiety, as seen in previous studies [35–37]. 
Furthermore, an anti-GFP antibody was used to quantify the bound 
nanocomplex or scGFP_PlGF2 to the stem cell plasma membrane, 
revealing the presence of the nanocomplex on the membrane for up to 
24 h (Supplementary Figure 15). 
This indicated that the mode of interaction with the plasma mem-
brane, i.e., charge vs hydrophobic insertion, impacted significantly on 
the rate of internalisation, potentially through an endocytic mechanism. 
The rapid endocytosis of supercharged proteins is well documented and 
has been actively utilised to develop novel transfection vectors and to 
promote tissue penetration of proteins [45–47]. Moreover, our previous 
studies using supercharged protein-polymer surfactant conjugates have 
indicated a clathrin-mediated endocytotic mechanism for both super-
charged proteins and their respective conjugates [35,37]. 
In order to estimate the number of constructs per cell, incubation 
solution depletion experiments were performed over a range of protein 
concentrations (Supplementary Figure 16). As the incubation concen-
tration was increased, both scGFP_PlGF2 and [S− ]scGFP_PlGF2 showed 
a steady increase in the number of constructs per cell that appeared to 
plateau at approximately 7.6 and 3.5 billion per cell, respectively. By 
considering the average cell plasma membrane area, this equated to 5 
and 2.5 layers of scGFP_PlGF2 and [S− ]scGFP_PlGF2 per cell, respec-
tively, which is indicative of strong protein-protein interactions leading 
to self-assembly at the membrane. Indeed, our previous work has shown 
that chemically supercharged proteins can undergo hierarchical self- 
assemble in vitro via a partial charge neutralisation process [48–50]. 
The multipotency of the hMSCs was not supressed by the introduc-
tion of scGFP_PlGF2 or [S− ]scGFP_PlGF2 to the plasma membrane. The 
hMSCs could still undergo osteogenesis (Alizarin red S stain and runx2 
mRNA expression; Supplementary Figure 17) or adipogenesis (Oil red O 
stain and pparg mRNA expression; Supplementary Figure 18) and the 
process was not observably or statistically different when compared to 
the untreated cell controls, respectively. Surprisingly, for experiments 
conducted in chondrogenic differentiation media, the transcription of 
the chondrogenesis marker gene col2a1 was upregulated for hMSCs 
modified with [S− ]scGFP_PlGF2 (Supplementary Figure 19). It is 
possible that this increased chondrogenic differentiation potential may 
have resulted from a reduction in the oxygen transport into the cells 
arising from the membrane coating, as hypoxic environments have been 
shown to drive chondrogenesis [51]. Additionally, sox9 was upregulated 
while collagen X was only negligible, indicating that all cells were 
committed to chondrogenic differentiation. However, as stem cells are 
extremely sensitive to their chemical and physical microenvironments, 
there are a plethora of other factors that may have contributed to this 
observation. 
2.4. The effect of hMSC membrane re-engineering on collagen type II 
affinity 
Collagen II comprises 95% of articular cartilage [52]. Accordingly, 
the ability of [S− ]scGFP_PlGF2 and scGFP_PlGF2 functionalised hMSCs 
Fig. 3. Live cell confocal images of human mesenchymal stem cells (hMSCs) 
after modification with the constructs. hMSCs were treated with either a 
scGFP_PlGF2 (green) or b [S− ]scGFP_PlGF2 (green) for 15 min at 37 ◦C and 
were imaged immediately after exposure. Cell nuclei were stained with Hoechst 
(blue) and cytoplasm was stained with a cell tracker (red). Scale bar = 50 μm. 
(For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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to adhere to collagen II was evaluated using a static adhesion assay. 
Suspensions of modified hMSCs were incubated in well-plates coated 
with either collagen II or bovine serum albumin (BSA) and the number 
of adherent hMSCs was evaluated by measuring the DNA content of each 
well. Importantly, there was a significant increase in the number of [S− ] 
scGFP_PlGF2 modified cells bound to the collagen II substrate when 
compared with either the unmodified control or the scGFP_PlGF2 pre-
cursor (Fig. 4a). This increased adhesion was attributed to the longer 
persistence time of the nanocomplex on the plasma membrane, when 
compared to the scGFP_PlGF2, which was internalised rapidly. More-
over, the orientation and hence the steric accessibility of the peptide in 
the scGFP_PlGF2 modified cells may have been reduced, as PlGF2 can 
bind to the neuropilin-1 (CD304) receptor present in low amounts on 
hMSCs, changing the orientation of the protein to allow the scGFP 
moiety face the ECM [53,54]. This different orientation is likely pre-
vented by the predominant surfactant hydrophobic anchoring to the cell 
membrane, making the PlGF2 domain face the surrounding available to 
interact with the ECM proteins. 
Additionally, the adhesiveness to non-cartilaginous intra-articular 
tissue, collagen I was also tested in static conditions, with no significant 
increase in hMSC adhesion after modification using scGFP_PlGF2 or [S− ] 
scGFP_PlGF2 (Supplementary Figure 20). 
Dynamic cell adhesion experiments to collagen II were also per-
formed under flow using a microfluidics chip to simulate the low shear 
stresses experienced in the synovium of the knee joint [55–57]. Adhe-
sion experiments performed at 0.75, 1.0 and 1.5 dyne cm− 2 all showed 
an increase in adhesion of hMSC modified with [S− ]scGFP_PlGF2 to 
collagen II, which was not apparent for the scGFP_PlGF2 modified cells 
(Fig. 4b–d). These data, along with the those generated using the static 
adhesion system, support a scenario where the PlGF2 peptide is 
addressable and can therefore bind to collagen II when presented on the 
surface of the hMSC using the [S− ]scGFP_PlGF2 nanocomplex. 
2.5. Adhesion of modified hMSCs to cartilage ex vivo explants 
To investigate the ability of the nanocomplex-modified hMSCs to 
bind to living AC, 6 mm bovine ex vivo articular explants from the lateral 
and patellar groove of 6–8 weekold calves were harvested 8 h post- 
mortem (see Experimental section 4.18). Bovine living explants are 
currently recognised as one of the best available models to represent 
articular cartilage [58]. Here, [S− ]scGFP_PlGF2-modified hMSCs in 
suspension (see Experimental section 4.11) were introduced to the 
cartilage explant substrates and left to adhere for 4 h before washing 
twice with PBS to remove unbound cells and treated for electron or light 
microscopy (see Experimental section 4.19 and 4.20). Significantly, 
scanning electron micrographs of the cartilage surface revealed that the 
[S− ]scGFP_PlGF2-modified hMSCs remained in greater numbers, when 
compared to the hMSC controls (Fig. 5a and b), which indicated 
increased adhesion to the articular surface. Moreover, fluorescence 
microscopy imaging of histology slices taken from ex vivo explants 
incubated for 4 h with the nanocomplex-modified hMSCs revealed a 
high concentration of the cells at the cartilage-media interface even after 
Fig. 4. Static and dynamic affinity assays. a Static 
affinity assay showing the human mesenchymal 
stem cells (hMSCs) adherence to immobilised 
collagen II after hMSCs were treated with 4 μM of 
either scGFP_PlGF2 (orange bars) or [S− ] 
scGFP_PlGF2 (blue bars) for 15 min, compared to 
the untreated cell controls (green bars). hMSCs 
were suspended in DMEM phenol free media 
without any supplements. The cells were added to 
the wells pre-coated with collagen type II (0.2 mg 
mL− 1) or bovine serum albumin (BSA, 10 mg 
mL− 1), and incubated for 4 h at 37 ◦C in a 5% CO2 
atmosphere. Cell attachment was measured by 
DNA quantification. Average represented as bars 
with standard deviation calculated using hMSCs 
from 4 different patients (n = 4). Dynamic affinity 
assay showing the hMSCs adherence to collagen II 
under shear at b 0.75 dyne cm− 2, c 1.00 dyne 
cm− 2, and d 1.5 dyne cm− 2. The cells were added 
at a density of 106 cells per mL in serum-free media 
into a reservoir in a VenaFluoro8 biochip coated 
with collagen type II (0.2 mg mL− 1), and bovine 
serum albumin (BSA, 0.1 mg mL− 1). Average rep-
resented as bars with standard deviation calculated 
using hMSCs from 3 different patients (n = 3). 
Comparison of differences was tested using an 
unpaired student t-test with a p-value < 0.05 and 
0.01 considered significant (*) and highly signifi-
cant (**) respectively. (For interpretation of the 
references to colour in this figure legend, the 
reader is referred to the Web version of this 
article.)   
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rinsing non-adherent cells and imaged after 24 h (Supplementary 
Figure 21). Semi-quantitative image analysis from confocal fluorescent 
images was also performed on the living cartilage explants after the 
addition of the nanocomplex modified hMSCs (Fig. 5c and Supplemen-
tary Figure 22). Significantly, when seeded onto the ex vivo bovine 
cartilage explants, the number of adhered hMSCs was two-fold higher 
after [S− ]scGFP_PlGF2 functionalisation, when compared with the un-
modified cell controls (Fig. 5c). 
The ability of the free nanocomplex, the scGFP_PlGF2 precursor, and 
scGFP to directly interact with chondrocytes within the ex vivo articular 
Fig. 5. Scanning electron microscopy images of human mesenchymal stem cells (hMSCs) on bovine explant surface. hMSCs were used unlabelled (a) or treated with 
4 μM of [S− ]scGFP_PlGF2 for 15 min (b), then seeded on bovine explant discs of 6 mm diameter and allowed to attach for 4 h at 37 ◦C in a 5% CO2 atmosphere in 
serum-free media. Samples were fixed, treated with osmium to improve contrast, dehydrated with ethanol, and coated with gold/palladium. b untreated hMSCs were 
taken as a control. c Adhesion assay in bovine ex vivo explants. hMSCs were treated for 15 min with [S− ]scGFP_PlGF2 (blue), using untreated cells as a control 
(green). hMSCs were suspended in DMEM phenol-free media without any supplements and added to 96-well plates containing 6 mm diameter living bovine explant 
discs. Cells were allowed to attach for 4 h at 37 ◦C in a 5% CO2 atmosphere. The explants were then imaged using confocal fluorescence microscopy, taking three- 
dimensional images in six random places, and the images were flattened and analysed using Fiji software. Average represented as bars with standard deviation 
calculated using 6 cartilage discs (n = 6). Comparison of differences was tested using an unpaired student t-test with a p-value < 0.05 and 0.01 considered significant 
(*) and highly significant (**) respectively, compared to control. Scale bar = 100 μm. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
Fig. 6. Bovine cartilage ex vivo explants discs directly exposed to the constructs. Discs were incubated in 1 μM solution of either scGFP (green, upper row), 
scGFP_PlGF2 (green, middle row), or [S− ]scGFP_PlGF2 (green, bottom row), respectively, with 1% bovine serum albumin. The cross sections were imaged after 24 h. 
Cell nuclei were stained with DAPI (blue). Scale bar = 100 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web 
version of this article.) 
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explants was also explored (Supplementary Figure 23). Previous reports 
have indicated that the degree and distribution of supercharging on a 
protein surface directly impacts on cartilage ECM penetration and dis-
tribution [59]. Moreover, recent studies have employed antibody-PlGF2 
fusions to improve adhesion in ex vivo collagen sheets [60]. All three 
constructs were able to interact with the explant substrates. The [S− ] 
scGFP_PlGF2 nanocomplexexhibited a strong interaction with the 
chondrocyte plasma membrane, with little evidence of endocytosis 
(Fig. 6). 
Conversely, both scGFP and scGFP_PlGF2 were rapidly internalised 
by the chondrocytes (Fig. 6), which signified that the magnitude of the 
affinity of the PlGF2 peptide for the ECM was overcome by active 
endocytosis of the highly supercharged protein. Indeed, the rapid pro-
cessing of the unconjugated protein constructs was reflected in super-
natant depletion experiments, which showed a greater uptake of scGFP 
and scGFP_PlGF2 (cf. [S− ]scGFP_PlGF2; Supplementary Figure 24), and 
corroborates the charge-dependence resulting from the coulombic 
attraction between the negatively charged cell membranes or ECM 
components and the positive charge of the scGFP moiety [59]. 
Furthermore, these results highlight the further utility of the scGFP 
systems and the importance of the surfactant in the nanocomplex, as it 
avoids aggregation, and it is retained on the ECM. 
3. Conclusion 
In this study, we demonstrated that hMSCs could be augmented with 
an artificial membrane binding nanocomplex to improve cartilage 
adhesion performance. This was achieved by harnessing the inherent 
ECM-binding affinity of a growth factor-derived peptide sequence, 
which could be readily displayed on the surface of hMSCs in high 
numbers and with sufficient duration. The hMSC membrane re- 
engineering protocol is facile and did not affect cell viability, prolifer-
ation, or differentiation. Importantly, hMSC adhesion to a key ECM 
component of cartilage, collagen II, was improved, as was the cell af-
finity for AC explants, despite the presence of endogenous anti-adhesive 
molecules. 
Comparison of the analogues [S− ]scGFP_PlGF2 nanocomplex and 
scGFP_PlGF2 protein revealed the importance of the surfactant corona 
on the protein, for instance, lower cytotoxicity, longer retention on the 
membrane, as well as enhanced adhesion under static and dynamic 
conditions to collagen II, the main component of hyaline cartilage. 
Our results support a mechanism whereby hydrophobic interactions 
drive [S− ]scGFP_PlGF2 association at the plasma membrane, promoting 
an end-on insertion of the scGFP motif [35,37,44], which is critical for 
effective binding of the PlGF2 peptide to the AC ECM proteins. More-
over, the nanocomplex membrane persistence (days) and number (ca. 
3.5 billion per cell) could help overcome the rapid loss of viable thera-
peutic cells at the site of injury through anoikis and incorrect targeting 
[21]. Indeed, the lack of viable transplanted cells is clearly a challenge 
across a range of stem cell therapies, and several genetic engineering 
approaches have been developed to improve hMSC performance 
(viability, mobility and proliferation) in injury environments [61]. 
When compared to these approaches, which have high costs and po-
tential side-effects subject to insertional oncogenesis [62], our approach 
leverages transient and potentially tuneable membrane display, the 
ability to plug in to existing cell manufacturing processes, and scalable 
protein production. Moreover, our simple one step cell membrane 
modification methodology is cell agnostic and could be readily extended 
to other therapeutic cell types (e.g., pluripotent stem cells or epithelial 
cells, etc.). It is our hope that these emerging cell therapy technologies 
will improve the efficacy of injectable stem cell treatments to drive 
clinical translation. Indeed, the next stage of the development of these 
artificial membrane binding nanocomplexes will involve generating 
compelling cartilage regeneration in vivo preclinical animal model data. 
4. Experimental 
4.1. scGFP_PlGF2 construct design, expression, and purification 
The plasmid with sequence N-His6-scGFP-PlGF2-C (Supplementary 
Tables 1 and 2) was designed for pOPIN F vector1 (Oxford Protein 
Production Facility; Addgene plasmid # 26,042), which is enhanced for 
multi-histidine tag purification under control of the lac-operon and 
designed for ampicillin resistance. The polymerase chain reaction (PCR) 
was used to amplify the gene sequence. A mix of 1 μM template scGFP- 
PlGF2, forward and reverse primers (each at 1 μM), 5 U μL− 1 of poly-
merase Labtaq Hi-Fidelity Polymerase™  (LabTech, UK) and reaction 
buffer 5x (LabTech, UK), plus DNase free water to make a final volume of 
50 μL, was added to a DNAse free 200 μL tube. This was subjected to PCR 
in a thermocycler (Thermo Fisher Scientific, UK) with the following 
settings: 95 ◦C for 5 min for initialization and heat activation of the DNA 
polymerases, 95 ◦C 30 s for denaturation at the beginning of each cycle, 
62 ◦C 30 s, 72 ◦C 3 min, 90 ◦C to 2 ◦C for 30 cycles, 72 ◦C for 10 min, and 
finally cooled at 4 ◦C. A 1.5% w/v agarose gel and stained with SYBR 
safe stain (Invitrogen, UK) to facilitate the separation and purification of 
the PCR products. For extraction, a QIAquick gel extraction kit was used 
as indicated by the manufacturer. 
For linearization, the vector (80 mg mL− 1) was added to cut smart 
buffer, 1 unit of restriction enzyme Hind III, 1 unit of Kpn I (New En-
gland BioLabs, UK), and nuclease-free water. The mixture incubated 
overnight at 37 ◦C. The sample mixture was then treated with a 
NucleoSpin Gel and PCR clean-up kit following the instruction of the 
manufacturer (Gmbg & Co. KG, Germany). The In-Fusion™  cloning 
method was used to insert the fusion gene into the linearized plasmid. 
Transformation in Competent Stellar Cells™  (Clontech, UK) was 
performed according to the manufacturer’s instructions. In summary, 
the In-Fusion™  mixture was added to Competent Stellar Cells™ , gently 
mixed, and then submitted to heat shock transformation for 45 s at 42 ◦C 
before being incubated in on ice. Subsequently, Super Optimal broth 
with Catabolite repression (SOC) medium was added before the cell 
suspension was incubated for 1 h at 37 ◦C. The cell suspension was then 
centrifuged at 12,000 g for 10 min, resuspended in 50 μL of SOC me-
dium, and was homogeneously distributed into LB agar plates contain-
ing carbenicillin (5 μg mL− 1). A single colony was selected from the LB 
agar plate and used to inoculate starter culture (Lysogenic broth with 
added carbenicillin 5 μg mL− 1), and left in rotating motion incubator at 
200 rpm over night at 37 ◦C. For plasmid DNA isolation and purification, 
a QIAgen Spin Miniprep kit was used according to the manufacturer’s 
instructions. For transformation in BL21 cells, an aliquot of purified 
plasmid scgfp-plgf2_123–144 (>100 ng mL− 1) was added to competent 
BL21 DE3 Escherichia coli (E. coli) cells (New England BioLabs, UK) and 
equilibrated on ice for 30 min. Heat shock was performed in a water bath 
at 42 ◦C for 10 s. The cell suspension was then equilibrated on ice for 5 
min before the addition of 950 μL of SOC media. The suspension was 
incubated for 60 min in shaking incubator at 200 rpm at 37 ◦C. The 
resulting mixture was centrifuged at 120 g for 5 min, and the superna-
tant was discarded. The cell pellet was resuspended in 50 μL of SOC 
medium and the suspension was used to inoculate freshly made LB agar 
plates, and incubated overnight at 37 ◦C. 
The gene sequence scgfp-plgf2_123–144 or scgfp was expressed using 
competent BL21 (DE3) E. coli cells. A single colony was chosen to 
inoculate autoclaved LB broth, containing carbenicillin (5 μg mL− 1) and 
incubated overnight at 37 ◦C rotating at 200 rpm. The cell suspension 
was then added to 1 L of autoclaved LB medium with 5 μg mL− 1 car-
benicillin and stirred at 200 rpm at 37 ◦C for approximately 4 h, until the 
optical density reached 0.6–0.8 (λ = 600 nm). Protein expression was 
induced using a final concentration of 10 mM of iso-
propylthiogalactosidase (IPTG; Apollo Scientific, Japan) and the cell 
suspension was incubated and agitated overnight at 200 rpm at 37 ◦C. 
The culture was centrifuged at 4000 g for 35 min at 4 ◦C, and the 
sediment was resuspended in lysis buffer (20 mM Tris HCl, 1 M NaCl and 
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20 mM imidazole at pH 7.5). Cells were lysed by sonication using a Vibra 
Cell VCX 1500 (Sonics & Materials, USA) at a 63% amplitude. Phyl-
methylsulfonyl fluoride (PMSF) solution (100 mM PMSF in dimethyl 
sulfoxide DMSO) was added before and after sonication, along with a 
sufficient amount of lyophilised DNase I from bovine pancreas. The 
lysed sample was centrifuged at 20,000 g for 30 min, the supernatant 
was filtered through a 0.22 μm cellulose membrane syringe filter and 
purified by immobilised metal affinity chromatography using nickel 
nitrilotriacetic acid (Ni-NTA) as the immobile phase. Using a XK 16 
column (GE healthcare life sciences, UK) containing 25 mL of Ni-NTA 
(Qiagen, UK). The column was washed with lysis buffer and 
increasing gradients of imidazole using ÄKTA purifier (GE Healthcare, 
UK) until eluted with high imidazole buffer (500 mM Tris HCl, 1 M NaCl 
and 20 mM Imidazole adjusted to pH 7.5 with concentrated HCl). The 
resulting purified protein was buffer exchanged into working buffer 
(400 mM NaCl, 20 mM Tris HCl, pH 7.5) using 14,000 MWCO cellulose 
dialysis tubing, (Fisher scientific, US) at 4 ◦C. The same method was used 
to purify scGFP. 
4.2. Polyacrylamide gel electrophoresis (SDS-PAGE) 
10 μL sample aliquots containing SAB (5% SDS, 50 mM ethyl-
endiaminetetraacetic acid (EDTA), 0.5 mM Tris and 7 mM β- mercap-
toethanol and bromophenol was added until dark blue) were denatured 
at 95 ◦C for 5 min. A 4–20% bis-tris gel (Invitrogen, USA) was sub-
merged into an X-Cell Surelock electrophoresis chamber (Thermo 
Fisher, UK) containing running buffer (50 mM Tris base, 38.5 mM 
glycine and 7 mM SDS). 10 μL of the denatured sample was added to 
each well, using a PageRuler Plus Prestained ladder (Thermo Fisher, UK) 
10–180 kDa as reference. Electrophoresis was performed using a 
continuous voltage of 200 V to the system for 60 min. The gel was 
removed from the cast and stained with Coomassie Blue™  and distained 
using solution containing 20% ethanol and 5% acetic acid for up to 2 h. 
4.3. Bicinchoninic acid (BCA) 
A Pierce BCA Protein Assay™  kit (Thermo Fisher scientific, UK) was 
used for this process. A stock solution for the working reagent (WR) was 
prepared according to the number of samples (200 μL of WR in a 96 well 
plate). This was prepared by mixing reagent A ([2,2′-Biquinoline]-4,4′- 
dicarboxylic acid, sodium salt) and B (Copper II sulphate pentahydrate) 
in a 50 to 1 ratio. An aliquot of 25 μL of scGFP_PlGF2 in solution was 
added to a 96 well plate (Costar, UK), followed by the addition of 200 μL 
of WR to the same well. The plate was incubated at 37 ◦C for 30 min and 
the absorption was measured at 562 nm with a multi-mode plate reader 
Synergy neo2 (BioTek, USA). Known concentrations of bovine serum 
albumin (BSA) were used to produce a standard curve. The slope of the 
linear regression equation line from the plotted graph from absorbance 
at 562 nm against concentration was taken to produce a standard curve. 
4.4. Matrix-assisted laser desorption/ionisation mass spectrometry time 
of flight (MALDI-TOF) 
The average molecular weight of the protein constructs and polymer 
surfactants were obtained using a Bruker MALDI mass spectrometer 
(Applied Biosystems, UK) running FLEX control software (Bruker, USA). 
The sample was prepared using 1:1 ratio of cinnamic acid matrix (50:50 
solution of acetonitrile and 0.1% TFA and saturate with α-Cyano-4- 
hydroxycinnamic acid), spotted 1 μL sample on rough steel plate and let 
dry at room temperature for 10 min before loading into the machine. 
Spectra were taken between 10 and 55 kDa for proteins and 0–5 kDa for 
surfactants. 
4.5. Protein-polymer surfactant nanocomplex [S− ]scGFP_PlGF2 
formation 
To form the nanocomplex [S− ]scGFP_PlGF2, the concentration of the 
protein scGFP_PlGF2 was evaluated using UV–vis light absorbance at 
280 and 487 nm over the wavelength range 200–600 nm. Beer-Lambert 
law was used to calculate the protein concentration where A is the 
absorbance at a wavelength of 280 nm and ε is the extinction coefficient, 
17,330 M− 1cm− 1 at 280 nm (Protein Calculator, RCSB Protein Data 
Bank). For fluorescence Spectroscopy, samples were analysed using a 
fluorescence spectrometer in Cary Eclipse fluorometer (Agilent Tech-
nologies, USA) using Cary Scan (Agilent Technologies, USA) software. 
Excitation and emission scans were performed from 350 to 600 nm. The 
surfactant was added in a ratio of 1.4 to 1 of surfactant molecules to 
positive sites, respectively. The solution was stirred overnight at 200 
rpm and it was then dialysed in a 14,000 MWCO cellulose bag into 400 
mM NaCl and 20 mM Tris at pH 7.5. 
4.6. Synchrotron radiation circular dichroism 
Synchrotron radiation circular dichroism (SR–CD) was performed at 
Diamond Light Source (Oxford, UK) on the B23 beamline. Spectra were 
measured from 180 to 260 nm, using a cylindrical cell with a 200 μm 
pathlength in a Linkam System. The beam current was 300 mA, the slit 
width was 1 mm, and the integration time was 2 s. The CD spectra were 
obtained over a temperature range of 24–90 ◦C with a measurement at 
every 3◦, and an equilibration time of 1 min per measurement. The 
resulting data were analysed and deconvoluted using BestSel Software 
[63], which trimmed the spectra to 190–250 nm and assessed the sec-
ondary structure features in this range. Particularly, this software con-
siders the existing twist in beta-structures and can differentiate between 
parallel and antiparallel beta sheets reliably to accurately predict the 
secondary structure over a wide range of proteins and is optimised for 
spectra obtained from SR–CD. The algorithm works with data taken 
from 175 nm and as accurately with data obtained from 190 nm. Protein 
samples were measured at concentrations between 3 and 3.6 mg mL− 1 in 
20 mM sodium phosphate buffer pH 7.5. 
4.7. Dynamic light scattering (DLS) and zeta potentiometry 
DLS and zeta potentiometry were performed using a ZetaSizer Nano 
ZS (Malvern Instruments, UK) and ZetaSizer software (Malvern In-
struments, UK). Samples were filtered (0.22 μm pore size) before mea-
surement, the parameters selected were 3 runs with 10 measurements 
each with 120 s of equilibration time. 
4.8. Protein structure modelling via iterative threading assembly 
simulations (I-TASSER) 
The input of the I-TASSER (https://zhanglab.ccmb.med.umich.edu/ 
I-TASSER/) structure prediction server was the scGFP_PIGF2 amino acid 
sequence (Supplementary table 2), with chain A of the crystal structure 
of superfolder GFP (PDBID: 2B3P:A) specified as a template [40,41]. 
4.9. Synchrotron radiation small angle X-ray scattering (SR–SAXS) 
SR–SAXS measurements were performed using the Diamond Light 
Source (Oxford, UK) mail-in service on beamline B21. The detector 
(Eiger 4 M) was used with a range from 0.0032 to 0.38 Å− 1. The beam 
size was <75 μm, operating with a fixed camera length at 4.014 m at 
12.4 keV. SR–SAXS measurements were coupled with size exclusion 
chromatography (SEC–SAXS) using a superdex 200 column (GE 
Healthcare). The data was collected in 30 successive frames, each with a 
1 s exposure time. The 60 μL samples at 4 mg mL− 1 were prepared by 
concentrating the purified constructs with a 10 MWCO spin concen-
trator (Merck, USA) until the desired concentration was achieved, and 
R. Cuahtecontzi Delint et al.                                                                                                                                                                                                                  
Biomaterials 276 (2021) 120996
9
verified with NanoDrop ND-1000 (Thermo Scientific, USA). The data 
were scaled, merged, and background subtracted buffer using ScÅtter 
software. This same software was also used to determine the Porod 
exponent (PE; the slope of a line of linear regression to the scattering data 
in the Porod–Debye region) [64] and to convert the data to real space 
distributions for further analysis with ATSAS plugins [65]. Briefly, a 
Fourier inversion was performed on the scattering data (I(q); equation 
1) to determine the pair-distance distribution function (P(r)), from 
which the radius of gyration (Rg), maximum dimension (Dmax), and the 
radial average (r) could be determined using ScÅtter software. Porod 
exponent. The output from ScÅtter was submitted to EMBL DAMMIF 
online service [66] in order to obtain a dummy atom bead model. 
Dummy atom bead models were fitted to the predicted 3-dimensional 







Equation 1. Fourier inversion of the scattering curve I(q) to obtain 
the pair-distance distribution function (P(r)). 
4.10. Human mesenchymal stem cell culture and membrane modification 
Human mesenchymal stem cells (hMSCs) were isolated from the 
proximal femur bone marrow of patients undergoing total hip replace-
ment surgery, according with the Bristol Southmead Hospital Research 
Ethics Committee guidelines (reference #078/01). All cell culture work 
was executed in SAFE 2020 laminar flow hoods (Thermo Fisher Scien-
tific, UK), and incubated in Hera cell 150 (Thermo Fisher Scientific, UK) 
at 37 ◦C under a 5% carbon dioxide atmosphere. hMSCs were expanded 
in monolayer using T25, T75 or T175 flasks (Fisher Scientific, UK) using 
5, 12, or 25 mL of culture medium respectively. The media was changed 
every 2 days. The hMSCs were expanded in complete media: DMEM 
containing NaHCO3, supplemented with 100 units⋅mL− 1 penicillin, 100 
μg mL− 1 streptomycin, 2 mM GlutaMAX supplement (Invitrogen, USA), 
10% v/v foetal bovine serum (FBS), and 5 ng mL− 1 of freshly added basic 
human fibroblast growth factors (FGF) (Peprotech, USA). 
4.11. Stem cell modification with nanocomplexes 
For membrane modification, hMSCs were seeded in well plates at 
desired density, and after adhesion to the plate, were incubated for 15 
and 30 min with 2 mL of scGFP_PlGF2 or [S− ]scGFP_PlGF2 and moni-
tored using widefield fluorescent microscopy (Leica LASX). As there was 
no observable difference in the fluorescence intensity between the cells 
treated for 15 or 30 min, an incubation time for 15 min used for all 
further experiments. hMSCs were also modified in suspension. Here, 
after trypsinisation and resuspension in phenol-free DMEM (without 
supplements), cells were incubated for 15 min at 37 ◦C with 2 mL of 4 
μM of either scGFP_PlGF2 or [S− ]scGFP_PlGF2 with agitation at 50 rpm. 
The hMSCs suspension was centrifuged at 220 g for 5 min to remove 
unbound constructs and resuspended in phenol-free DMEM without 
supplements at desired density. 
4.12. Cell metabolic activity and proliferation 
An MTS colorimetric assay CellTiter 96 kit (Promega, USA) was used 
to measure the total metabolic rate of hMSCs as an indication of 
viability. hMSCs in monolayer were exposed to a range of different 
concentrations of scGFP_PlGF2 and [S− ]scGFP_PlGF2 (2, 4, 6, 12 and 18 
μM) in triplicate for 15 min at 37 ◦C. The same principle was applied to 
measure the metabolic activity of hMSCs after being exposed for 15 min 
to different concentrations (0.5, 2, 4, and 10 mg mL− 1) of free oxidised 
IGEPAL co-890. These concentrations were equivalent to the conjugated 
surfactant concentration in [S− ]scGFP_PlGF2, e.g. for a protein con-
centration of 2.75 μM, 0.5 mg mL− 1 of surfactant was added to form the 
nanocomplex. The absorbance of formazan was measured at 490 nm 
after 2 h using microplate Mithras LB 140 (Berthold technologies, Ger-
many). For cell proliferation, hMSCs were suspended in phenol-free 
DMEM (without supplements) and treated for 15 min at 37 ◦C with 2 
mL of 4 μM of scGFP_PlGF2 and [S− ]scGFP_PlGF2 with agitation at 50 
rpm. Cells were separated from unbound constructs by centrifugation at 
220g or 5 and resuspended in phenol-free DMEM without supplements 
and counted. 100,000 cells were seeded in a T25 flask with 5 mL of 
culture medium containing 5 ng mL− 1 of FGF. The medium was changed 
every two days. After seven days, cells were harvested, counted, and 
seeded at the initial density. 
4.13. Flow cytometry 
hMSCs were resuspended in DMEM phenol-free medium and 
exposed to 2 mL of 4 μM scGFP_PlGF2 or [S− ]scGFP_PlGF2 for 15 min 
inside an incubator at 37 ◦C with agitation at 50 rpm. The cell suspen-
sion was centrifuged at 220 g for 5 min and the pellet resuspended in 
flow cytometry buffer (2% v/v FBS, 2.5 mM EDTA in PBS), at 1 × 106 
cells per mL with 0.004 mg mL− 1 of propidium iodide (PI). The cell 
suspension was transferred to flow cytometry tubes (VWR, UK). Samples 
were analysed with NovoCyte flow cytometer (ACEA Biosciences, USA) 
and analysed using NovoExpress software (ACEA Biosciences, USA). 
Parameters were set to 100–300 events per second with 20,000 events 
accumulated for gate analysis. Untreated cells were used to define the 
four gates as follows: whole cells by forward scatter height (FSC–H) vs 
side scatter height (SSC–H), single cells by forward scatter area (FSC-A) 
vs (FSC–H), PI negative living cells by FSC-A vs Qdot605A and positively 
labelled cells with GFP were defined by FITC-A vs FSC-A. 
To quantify the amount of scGFP_PlGF2 or nanocomplex on the 
surface of the cells, an anti-GFP antibody (Biolegend, UK), with an APC 
fluorophore (Ex/Em = 650/660 nm) was used for co-localisation. 
hMSCs were seeded at a density of 50,000 cells per well and exposed 
to 2 mL of 4 μM scGFP_PlGF2 or [S− ]scGFP_PlGF2 for 15 min inside an 
incubator at 37 ◦C. The modified hMSCs were detached using trypsin/ 
EDTA solution for 5 min at 37 ◦C, rinsed with complete DMEM con-
taining serum, transferred to 14 cm flow cytometry tubes and rinsed 
with PBS. The supernatant was discarded, and 100 μL of a 1:50 antibody 
solution in PBS was added to the cells and gently mixed using a pipette. 
The cell suspension was incubated at 4 ◦C for 20 min and 2 mL of PBS 
were added to each tube. The solution was centrifuged at 220 g for 5 min 
and the cells were resuspended in 100 μL of PBS and submitted for flow 
cytometry quantification immediately using MACSQUANT X (Miltenyi, 
Germany) instrument. The data was analysed using FlowJo software. 
Parameters were set to 100–300 events per second taking 80 μL of so-
lution every time. Untreated cells labelled with the anti-GFP antibody 
were used to define the gates as follows: whole cells by forward scatter 
height (FSC–H) vs side scatter height (SSC–H), single cells by forward 
scatter area (FSC-A) vs (FSC–H), positively labelled cells with GFP were 
defined by FITC-A vs SSC-A, and antibody labelled cells were defined by 
APC-A vs SSC-A. The median fluorescence intensity of the APC gate was 
taken to graph the results. 
4.14. Evaluating the average number of constructs per cell 
hMSCs were seeded at a density of 20,000 cell per well and treated 
with 0.25, 0.5, 2, 4 and 6 μM solutions of scGFP_PlGF2 or [S− ] 
scGFP_PlGF2 for 15 min at 37 ◦C in an incubator. The supernatant was 
aspirated and collected for UV–vis analysis, taking a full spectrum from 
200 to 600 nm. The absorption intensity at 487 nm was compared to the 
known initial absorption and the number of biohybrid constructs on the 
surface of hMSCs was estimated through the reduction in total construct 
in the supernatant. 
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4.15. Live cell light microscopy 
For confocal fluorescence microscopy (Leica SP8), 40,000 hMSCs 
were seeded in glass bottom micro well dishes 35 mm (MatTek, USA) 
with culture media and allowed to adhere overnight. The nucleus was 
stained with of Hoechst 33,342 (Fisher scientific H3570) and the cyto-
plasm using of Cell Tracker red CMTPX dye (Life technologies C34552) 
for 30 min at 37 ◦C under 5% CO2 atmosphere. This media was then 
aspirated and replaced with 2 mL of 4 μM of sample scGFP_PlGF2 or [S− ] 
scGFP_PlGF2. Cells were incubated for 15 min, washed twice with 1 mL 
of PBS, and then immersed in 2 mL of complete phenol-free medium. 
For time lapse widefield fluorescence microscopy, hMSCs were 
seeded at a density of 20,000 cells per well, in tissue cultured treated 6 
well plate 34.8 mm (Corning, UK) with supplemented culture media 24 
h previous to the experiment. The nucleus was stained with Hoechst 
33,342 (Fisher scientific H3570) for 20 min at 37 ◦C under 5% CO2 at-
mosphere. This media was then aspirated and replaced with 2 mL of 4 
μM of sample scGFP_PlGF2 and [S− ]scGFP_PlGF2. Cells were incubated 
for 15 min, then washed twice with 1 mL of PBS. Finally, 2 mL of sup-
plemented phenol-free medium DMEM was added. The cells were ana-
lysed using an inverted microscope (Leica LASX DMI6000) with a 20x 
lens at 37 ◦C under CO2 atmosphere for 12 h, taking one image every 15 
min. 
4.16. hMSC differentiation staining and qPCR 
For osteogenesis and adipogenesis differentiation, 20,000 hMSCs 
were seeded in a 12 well plate, using cells from three different patients. 
The cells were exposed to 300 μL of scGFP_PlGF2 or [S− ]scGFP_PlGF2 
for 15 min and rinsed twice with PBS. The cells were cultured in 
StemPro™  Osteogenesis differentiation medium (Thermo Fisher Sci-
entific, UK), StemPro™  Adipogenesis cell medium (Thermo Fisher 
Scientific, UK), or complete hMSC culture medium, with media changes 
every two days. Antifungal water (100 units of penicillin, 100 μg 
streptomycin and 2.5 μg of amphotericin in autoclaved dH2O) was 
added to fill the remaining wells of the plate. 
For osteocyte detection, sample wells were gently washed with 500 
μL pf PBS twice, then cells were fixed with 4% paraformaldehyde (PFA) 
(BioLegend, USA) for 30 min at room temperature. The cell monolayer 
was washed with 500 μL of autoclaved dH2O before adding 500 μL of 
filtered solution of Alizarin Red S (2% w/v Alizarin Red S, pH adjusted to 
4.1 with HCl). The plate was incubated for 30 min at room temperature 
in the dark and washed four times with 1 mL of autoclaved dH2O, and 
PBS was added prior to imaging. The samples were immediately imaged 
with a widefield inverted microscope and analysed with Fiji software 
(NIH, USA). All images were converted into a 16-bit image and a mean 
threshold was applied. Then, each image was submitted to particle 
analysis, using 0 to infinity size and 0 to 1 circularity for the total area 
covered by the stained monolayer. 
For adipocyte detection, the medium was removed by pipetting and 
the sample wells were washed twice with 500 μL of PBS. 500 μL of 
neutral buffered formalin 10% (10% of 37–40 formaldehyde, 90% 
dH2O, 33.5 mM sodium phosphate monobasic NaH2PO4, and 45.5 mM 
sodium phosphate dibasic Na2HPO4) to cover the cell monolayer, this 
was incubated at room temperature. After 45 min, fixation buffer was 
aspirated, and the wells were washed with 500 μL of autoclaved dH2O 
followed by the addition of 500 μL of 60% isopropanol solution and 
incubated at room temperature for 5 min. The isopropanol was aspirated 
and Oil Red O staining solution (stock 0.3% Oil Red O in isopropanol, 3 
parts diluted in 2 parts of autoclaved dH2O) was added to fill the wells, 
filtering the solution right before staining. Cells were incubated for 30 
min and the wells were washed several times with dH2O. Images were 
taking using widefield inverted microscope. 
For differentiation assays, cells from three different patients were 
seeded in a 6 well plate at a density of 50,000 cells. Cells were exposed to 
1 mL of 4 μM of scGFP_PlGF2 or [S− ]scGFP_PlGF2 for 15 min in 
incubator at 37 ◦C. The wells were gently rinsed twice with 2 mL of PBS 
and then 2 mL of chondrogenesis media (4500 mg mL− 1 glucose phenol- 
free DMEM containing pyridoxine-HCl and NaHCO3, supplemented with 
100 units⋅mL− 1 penicillin and 100 μg mL− 1 streptomycin, 2 mM Glu-
taMAX, 1 mM sodium pyruvate and 1% v/v insulin transferrin selenium 
ITS solution), freshly supplemented 0.01% v/v dexamethasone, 80 nML- 
ascorbic acid 2-phosphate, and 10 ng mL− 1 of TGF-β3 (R&D Systems, 
USA), changing media every two days. The same principle was used for 
osteogenesis and adipogenesis, using StemPro prepared media and 
serum (Gibco, UK). 
The cells were lysed to extract RNA with a Qiagen micro RNasy kit. 
The purified RNA was immediately processed for cDNA preparation, 
using a Takara PrimeScript RT reagent kit (Takara, Japan) according to 
the instructions provided by the manufacturer. This was performed in 
200 μL RNase free PCR tubes, and the resulting mix was summited to 
PCR at 37 ◦C for 15 min, 85 ◦C 5 s and 4 ◦C for cooling. The resulting 
cDNA was immediately used or stored at − 80 ◦C for future analysis. A 
MicroAmp Fast Optical 96-well reaction plate (Applied biosystems, UK) 
was used. On each well, 5.5 μL of a mixture containing 5 μL of Τaqman 
master mix and 0.5 μL of the gene set were deposited on the left wall of 
the well. Followed by the addition of 1 μL cDNA of the sample with 3.5 
μL of DNase-free water. The 96 well plate was covered with adhesive 
PCR plate film (Thermo Fisher Scientific, UK). qPCR was carried out 
using a QuantStudioTM 3D Digital PCR System (Life Technologies). The 
data obtained was analysed using the double delta Ct analysis method. 
4.17. Static and dynamic hMSC collagen adhesion assays 
For static adhesion measurements, a non-tissue culture treated 96 
well plate (Fisher, UK) was used to assess adhesion of treated cells. 100 
μL of either 0.2 mg mL− 1 collagen II from bovine tracheal cartilage 
(Sigma C1188, UK), collagen I from rat tail, or 10 mg mL− 1 BSA (control) 
was added to each well in triplicate and left at 4 ◦C overnight. The next 
day, wells were rinsed twice with 100 μL of PBS and non-specific binding 
sites were blocked with BSA solution 10 mg mL− 1 for 1 h. hMSCs were 
counted and treated in suspension with either scGFP_PlGF2 or [S− ] 
scGFP_PlGF2. 10,000 cells were seeded in each well with 100 μL of 
DMEM phenol-free medium with no additives and incubated at 37 ◦C in 
a 5% CO2 atmosphere. A standard curve was also made with different 
cell densities adding DMEM medium with all supplements in a tissue 
culture treated plate. After 4 h, the media was aspirated, and the wells 
were rinsed with 100 μL of PBS twice. DNA quantification assay 
(CyQUANT NF cell proliferation assay kit, Invitrogen) was performed, 
briefly, 100 μL of solution was added to each well and incubated for 60 
min, fluorescence was measured with a microplate reader with excita-
tion at 485 nm and emission at 530 nm. 
Dynamic cell adhesion experiments were carried out with a Micro-
fluidic pump ExiGo (Cellix Ltd, UK), with a shear stress precision of 
±0.5%. All channels of the Vena8 Fluoro + biochip (Cellix Ltd, UK) were 
coated with 0.1 mg mL− 1 collagen II from bovine tracheal cartilage 
(Sigma, UK) and left overnight at 4 ◦C in a humidified chamber. Non- 
specific sites were blocked with 10 μg mL− 1 BSA. hMSCs were modi-
fied and resuspended at a density of 1 × 106 cells per mL in DMEM 
phenol-free medium without additives. Each channel was first washed 
with DMEM phenol-free medium with no additives for 30 s at 40 μL 
min− 1. Then, a 50 μL aliquot of cells modified with scGFP_PlGF2 and 
[S− ]scGFP_PlGF2 or unmodified cells, were added into the channel 
reservoir each time, and the suspension was withdrawn with a flow rate 
of 6, 4 and 3 mL min− 1. A real-time video of 10 s was recorded at 113 ms 
per frame at the five marked positions in the biochip, using (Leica LASX 
DMI6000). In the same way, Vena8 Fluoro + biochip (Cellix Ltd, UK) 
was coated with 10 μg mL− 1 BSA to be used as a negative control. 
4.18. Bovine ex vivo explants harvest and preparation 
Cartilage explants were harvested form the lateral and patellar 
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groove of 6–8-week-old calves, obtained 6–8 h after death. The legs were 
carefully washed and disinfected with Rely + On Virkon (Dupont, UK) 
and warm dH2O. The skin from the legs was carefully removed with 22- 
size surgical blades (Swann-Morton, UK) until the coronet to reveal the 
joint area. The hoofs and the top side of the leg were covered in 
aluminium foil and the exposed surface of the leg was sprayed with 70% 
ethanol in dH2O and placed inside a laminar hood. The outer layer of 
tissue was removed to expose the articular cartilage, lateral and medial 
meniscus and to cut the anterior cruciate ligament. Cartilage disks from 
the lateral and patellar grove were delimited with an 8 mm biopsy punch 
(Stiefel, Germany) and carefully detached with a 22-size surgical scalpel 
(Swann-Morton, UK) and collected using tweezers (Supplementary 
Figure 23a). The discs were placed into falcon tubes in PBS containing 
1% penicillin/streptomycin solution. After dissection, the pieces were 
placed in individual wells in a 48 well plate (Corning, UK) and kept in 
phenol-free medium fully supplemented with antibiotics. 
Cartilage discs were washed twice in PBS before being cut to 6 mm 
diameter with a biopsy punch (Stiefel, Germany) and placed in a non- 
tissue culture treated 96 well plate (Fisher, UK) with 200 μL of DMEM 
phenol-free medium without supplements. Tissue discs were then 
stained with Hoechst nuclei stain for 5 min hMSCs were treated with 
[S− ]scGFP_PlGF2, and resuspended in DMEM phenol-free medium, 
using untreated cells as a control stained with CellTracker deep-red. 
hMSCs were counted and added onto the cartilage surface (20,000 
cells) and placed in incubator at 37 ◦C with 5% CO2 for 4 h. The samples 
were then used for confocal analysis, fixed for scanning electron mi-
croscopy SEM imaging or histology analysis. 
4.19. Scanning electron microscopy and histology from bovine explants 
All tissue samples were fixed with 2.5% glutaraldehyde for 1 h, and 
then were rinsed three times for 10 min with 100 mM sodium phosphate 
buffer pH 7.4. Cartilage samples were then placed in 1% osmium te-
troxide for 1 h, and then washed three times for 10 min with 100 mM 
sodium phosphate buffer and washed with dH2O for 10 min. De-
hydrations steps were made with 25, 50, 70, 80, 90, 96, 100% ethanol 
before being processed with critical point dryer (CPD) Leica EM 
CPD300, set for 15 cycles of 15 ◦C for cooling and slow heating at 35 ◦C, 
with slow CO2 exchange. The samples were carefully removed from the 
CPD machine and mounted on a SEM specimen stub (Ted Pella, USA) 
with a conductive carbon mount grip on top. The dry samples were 
placed in a high-resolution sputter coater (Agar Scientific, UK) and 
coated with 15 nm from gold/palladium filament. All samples imaged 
on Quanta 200 FEI field emission scanning electron microscopy (Thermo 
Fisher Scientific, UK). 
For histology, after hMSCs were seeded on ex vivo explants, the 
samples were fixed in 10% neutral buffered formalin overnight at room 
temperature. The tissue pieces were then bathed in 30% sucrose for 
cryo-sectioning or 70% ethanol. The slices were stained with DAPI as a 
counterstain to visualize chondrocyte residing cells in the tissue. 
4.20. Stem cell adhesion quantification on ex vivo explants 
Using a confocal microscope (Leica SP8), six explants with seeded 
hMSCs were imaged taking six three-dimensional Z-stack images in 
random allocations. The three-dimensional Z-stack images were flat-
tened to 2D using the Z-project function from the Fiji software package 
(NIH, USA). Then, a median intensity threshold was applied to the im-
ages and the resulting image was changed into binary with a watershed 
segmentation. Finally, the number of cells were counted excluding sizes 
smaller than 10 μm. 
4.21. Direct membrane functionalisation of cells in bovine cartilage 
explants 
This method was adapted from Krishnan et al. [59]. The 6 mm 
cartilage bovine ex vivo explants were first stained with Hoechst to 
identify the nuclei of the chondrocyte resident population. Then, the 
cartilage discs were submerged in a 1 μM solution of either scGFP, 
scGFP_PlGF2 or [S− ]scGFP_PlGF2 with 1% BSA in 1.5 mL Nalgene tubes 
for 24 h in a CO2 atmosphere at 37 ◦C. The supernatant was collected 
and submitted to UV–vis analysis taking a spectrum of each solution 
from 200 to 600 nm. The analysis of the 487 nm absorbance peak was 
used to quantify the protein deposited on the cartilage. All discs were 
then fixed in 4% paraformaldehyde (PFA) overnight. A vertical cross 
section of the discs was cut and analysed using confocal microscopy. 
4.22. Statistical analysis 
All the data obtained was statistically analysed using a student T-test 
with two-tailed unpaired samples in Microsoft Excel. Differences be-
tween the experimental and control groups were compared. The data 
was expressed as a mean of at least three biological repeats ±standard 
deviation. A value of p < 0.05 was considered statistically significant 
and labelled with asterisks (*: p < 0.05 and **: p < 0.01). 
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